Nothing Special   »   [go: up one dir, main page]

UA115436C2 - Протираковий злитий протеїн - Google Patents

Протираковий злитий протеїн

Info

Publication number
UA115436C2
UA115436C2 UAA201408554A UAA201408554A UA115436C2 UA 115436 C2 UA115436 C2 UA 115436C2 UA A201408554 A UAA201408554 A UA A201408554A UA A201408554 A UAA201408554 A UA A201408554A UA 115436 C2 UA115436 C2 UA 115436C2
Authority
UA
Ukraine
Prior art keywords
domain
fusion protein
sequence
terminus
amino acid
Prior art date
Application number
UAA201408554A
Other languages
English (en)
Inventor
Єжи Щепан Пєчиколан
Себастіан Домінік Павлак
Бартломей Мацєй Жерек
Пьотр Каміл Рузга
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of UA115436C2 publication Critical patent/UA115436C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04003—Phospholipase C (3.1.4.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Винахід належить до злитого протеїну, що містить домен (а), яким є функціональний фрагмент послідовності розчинного протеїну hTRAIL, причому даний фрагмент починається амінокислотою в позиції не нижче ніж hTRAIL95 і закінчується амінокислотою в позиції hTRAIL281, або гомолог згаданого функціонального фрагменту, і принаймні один домен (b), яким є послідовність цитолітичного ефекторного пептиду, що утворює пори в клітинній мембрані, при цьому послідовність домену (b) приєднана в точці С-кінця і/або точці N-кінця домену (а).
UAA201408554A 2011-12-28 2012-12-22 Протираковий злитий протеїн UA115436C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397595A PL223487B1 (pl) 2011-12-28 2011-12-28 Przeciwnowotworowe białko fuzyjne
PCT/IB2012/057657 WO2013098755A2 (en) 2011-12-28 2012-12-22 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
UA115436C2 true UA115436C2 (uk) 2017-11-10

Family

ID=47716118

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201408554A UA115436C2 (uk) 2011-12-28 2012-12-22 Протираковий злитий протеїн

Country Status (28)

Country Link
US (1) US20140377216A1 (uk)
EP (1) EP2797950B1 (uk)
JP (1) JP6324905B2 (uk)
KR (1) KR20140110017A (uk)
CN (1) CN103987728B (uk)
AU (1) AU2012360086B2 (uk)
BR (1) BR112014015922A2 (uk)
CA (1) CA2859494A1 (uk)
CY (1) CY1120055T1 (uk)
DK (1) DK2797950T3 (uk)
EA (1) EA201491277A1 (uk)
ES (1) ES2655828T3 (uk)
HK (1) HK1201848A1 (uk)
HR (1) HRP20180012T1 (uk)
HU (1) HUE035794T2 (uk)
IL (1) IL232834A (uk)
LT (1) LT2797950T (uk)
MX (1) MX352796B (uk)
NO (1) NO2797950T3 (uk)
PH (1) PH12014501363A1 (uk)
PL (2) PL223487B1 (uk)
PT (1) PT2797950T (uk)
RS (1) RS56758B1 (uk)
SG (1) SG11201403282QA (uk)
SI (1) SI2797950T1 (uk)
UA (1) UA115436C2 (uk)
WO (1) WO2013098755A2 (uk)
ZA (1) ZA201405460B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
GB201406705D0 (en) 2014-04-15 2014-05-28 Univ Liverpool Fusion proteins,polynucleotides,expression vectors, and their uses
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN107216385A (zh) * 2017-05-19 2017-09-29 何向锋 肿瘤特异性重组水蛭素及其制备方法和用途
WO2018219301A1 (zh) * 2017-05-31 2018-12-06 四川大学华西医院 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US11633363B2 (en) * 2017-09-27 2023-04-25 Emory University Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto
CN111909275A (zh) * 2019-05-08 2020-11-10 上海大学 延长多肽药物循环半衰期的靶向载药体系及其构建方法
CN110669146B (zh) * 2019-10-24 2023-05-23 常州大学 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도
CN114031673B (zh) * 2021-12-22 2023-09-22 杭州长龄生物科技有限公司 一种多肽及其制备方法
CN114605517B (zh) * 2022-05-12 2022-09-27 广东海洋大学 一种具有广谱抗癌作用的多肽lxp-7及其应用
CN116063389B (zh) * 2022-08-23 2023-07-07 广州医科大学 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500102A (ja) 1993-04-28 1997-01-07 ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー 細胞指向性溶解孔形成剤
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
EP1666591B1 (en) 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
EP1688498B1 (en) 2003-11-03 2011-03-09 Beijing Sunbio Biotech Co., Ltd. A recombinant protein with cancer suppression action, its encoding gene and use
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
EP2306200A1 (en) 2005-08-16 2011-04-06 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAILl by testing for GalNac-T14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CN102089320B (zh) * 2008-01-24 2015-11-25 埃斯佩兰斯医药公司 溶解结构域融合构建体及其制备和使用方法
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.

Also Published As

Publication number Publication date
AU2012360086A1 (en) 2014-08-07
PL397595A1 (pl) 2013-07-08
SI2797950T1 (en) 2018-02-28
NO2797950T3 (uk) 2018-03-17
CN103987728B (zh) 2017-05-10
DK2797950T3 (en) 2018-01-22
IL232834A0 (en) 2014-07-31
ZA201405460B (en) 2015-04-29
BR112014015922A2 (pt) 2020-10-27
RS56758B1 (sr) 2018-04-30
EP2797950B1 (en) 2017-10-18
NZ627445A (en) 2016-01-29
SG11201403282QA (en) 2014-07-30
JP2015504052A (ja) 2015-02-05
MX2014008028A (es) 2014-08-21
JP6324905B2 (ja) 2018-05-16
CN103987728A (zh) 2014-08-13
EA201491277A1 (ru) 2014-09-30
HUE035794T2 (en) 2018-05-28
LT2797950T (lt) 2018-02-12
PH12014501363A1 (en) 2014-09-22
KR20140110017A (ko) 2014-09-16
EP2797950A2 (en) 2014-11-05
AU2012360086B2 (en) 2016-12-22
HRP20180012T1 (hr) 2018-02-09
US20140377216A1 (en) 2014-12-25
ES2655828T3 (es) 2018-02-21
WO2013098755A2 (en) 2013-07-04
WO2013098755A3 (en) 2013-08-29
HK1201848A1 (en) 2015-09-11
IL232834A (en) 2017-09-28
PL223487B1 (pl) 2016-10-31
PT2797950T (pt) 2018-01-24
CA2859494A1 (en) 2013-07-04
MX352796B (es) 2017-12-07
CY1120055T1 (el) 2018-12-12
PL2797950T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
MX352796B (es) Proteina de fusion anticancerigena.
PH12014501083A1 (en) Anticancer fusion protein
MX2013007872A (es) Proteina de fusion anticancer.
MX2013006213A (es) Proteina de funsion anticancer.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
MX2020010399A (es) 3-epimerasa.
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2012143477A3 (en) Anticancer fusion protein
WO2016004906A3 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
PH12018502451A1 (en) Brain delivery protein
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
GB0818080D0 (en) Immunogenic peptides
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
UA108911C2 (xx) Протираковий злитий протеїн
WO2011150897A3 (es) Método para la terapia del cáncer